Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Exclusives

More »

For full access to this article login to GEN Select now.

Jun 25, 2014

Low Patient Enrollment Threatens Cancer Trials

Answers include less red tape, more communication and coordination; study cites need for more accrual data.

Low Patient Enrollment Threatens Cancer Trials

Industry cost-cutting and fewer physicians participating in clinical trials are among the hurdles to cancer R&D listed in a recent report. [© michaeljung - Fotolia.com]

  • Just 2% to 5% of adult patients now enroll in U.S. cancer trials, according to estimates offered over the past 15 years—a distressingly ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.
    •  


Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »